A director at LNA Sante Sa bought 132,140 shares at 26.351EUR and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Virbac: Public Release of the Year-End Consolidated Accounts at 31 December 2025 Public release of Virbac Consolidated Accounts at 31 December 2025. The Group released its 2025 Consolidated Accounts. The document is available on the corporate website, at corporate.virbac.com, under “Investors”, “Financial Reports”. The accounts were audited by the statutory auditors and examined by the board of directors on March 17, 2026. The report of the statutory auditors is in the process of being issued. Attachment
Virbac: Communiqué de mise à disposition des comptes consolidés au 31 décembre 2025 Communiqué de mise à disposition des comptes consolidés au 31 décembre 2025. Le Groupe annonce avoir mis à la disposition du public ses comptes consolidés au 31 décembre 2025 sur le site internet du Groupe, à l’adresse corporate.virbac.com, dans la rubrique « Investisseurs», puis « Rapports financiers. Les comptes consolidés ont été audités par les commissaires aux comptes, et examinés par le conseil d’administration en date du 17 mars 2026. Le rapport des commissaires aux comptes est en cours d’émission....
Virbac: 2025 annual results A robust adjusted EBIT margin² of 16.3% at CERS, driven by solid organic revenue growth of 7.9% Solid 2025 dynamic with annual revenue up +7.9% at CERS; with strong momentum in key categories and countries. Volume/mix effect of ~+5%, completed by price increase of ~+3%Adjusted EBIT (before amortization of assets arising from acquisitions) margin of 16.3% at CERS despite: temporary shutdown of an antigen’s production site and higher inventory write-offs in FY25partially offset by a solid underlying performance on sales prices and product mix and;improving operati...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.